Product Images Dihydroergotamine Mesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Dihydroergotamine Mesylate NDC 24201-463 by Hikma Pharmaceuticals Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - chemstruct

Chemical Structure - chemstruct

Dihydroergotamine mesylate is a chemical compound with the molecular formula C33H37N505°CH4035 and a molecular weight of 679.78. Additional information is not available.*

figure1.jpg - figure1 updated

figure1.jpg - figure1 updated

The text describes a figure (Figure 1) that shows the estimated probability of a patient responding to a study medication (Dihydroergotamine mesylate nasal spray) as a function of time elapsed since the start of treatment. The study was conducted in two groups (Dihydroergotamine mesylate N=208, Placebo N=200) and the response was measured during the four hours following a single 2 mg dose of the medication. The figure shows a graph with the estimated probability of response to the medication over time. No information is provided on what kind of study was conducted or what the medication is intended to treat.*

figure2.jpg - figure2 update

figure2.jpg - figure2 update

This is a graph labeled "Figure 2" that shows the estimated probability of a patient responding to Dihydroergotamine mesylate nasal spray during the four hours following dosing. The x-axis indicates time measured in hours since the first dose, and the y-axis shows the probability of response as a percentage. The graph displays four curves representing response rates for Studies 3 and 4 of Dihydroergotamine mesylate (N=97) and placebo (N=100). The data suggest that Dihydroergotamine mesylate may improve patient response over placebo within the four hours following dosing.*

figure3.jpg - figure3 update

figure3.jpg - figure3 update

This is a graph depicting the estimated probability of patients using additional treatments for migraine after 24 hours. The study looks at patients who received either dihydroergotamine mesylate nasal spray 2 mg or a placebo and measures the probability of analgesic use. The x-axis denotes the hours after the first spray, while the y-axis represents the probability percentage. The graph has different colored lines, and each has a unique pattern. The labels indicate the placebo's probability of use (represented by a dotted line) and those who received dihydroergotamine mesylate nasal spray (represented by a solid line).*

4mg-ml-carton.jpg - multi pack carton

4mg-ml-carton.jpg - multi pack carton

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.